ATARA BIOTHERAPEUTICS, INC. Increase (Decrease) in Other Current Liabilities
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Increase (Decrease) in Other Current Liabilities of $81.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was $247.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$166.00K, a 104.75% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was -$839.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was -$2.24M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2025 was -$4.52M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2024 was -$12.50M, a 213.02% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2023 was $11.06M, a 435.27% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in other current liabilities for fiscal 2022 was $2.07M, a 27.75% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $81.00K 10-Q · filed 2026-08-12 | -$758.00K derived: sum of 3 quarters · filed 2026-08-12 | -$3.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$166.00K 10-Q · filed 2026-05-12 | -$1.00M derived: sum of 2 quarters · filed 2026-05-12 | -$3.24M derived: sum of 3 quarters · filed 2026-05-12 | -$8.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$3.08M derived: sum of 2 quarters · filed 2026-03-16 | -$8.01M derived: sum of 3 quarters · filed 2026-08-12 | -$4.52M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$7.17M derived: sum of 2 quarters · filed 2026-08-12 | -$3.68M 10-Q · filed 2025-11-12 | -$5.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$4.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.44M 10-Q · filed 2026-08-12 | -$3.50M derived: sum of 3 quarters · filed 2026-08-12 | -$6.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.49M 10-Q · filed 2026-05-12 | $1.44M derived: sum of 2 quarters · filed 2026-05-12 | -$1.42M derived: sum of 3 quarters · filed 2026-05-12 | -$8.27M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$4.91M derived: sum of 2 quarters · filed 2026-03-16 | -$11.76M derived: sum of 3 quarters · filed 2026-03-16 | -$12.50M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$2.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$9.70M derived: sum of 2 quarters · filed 2025-11-12 | -$10.45M 10-Q · filed 2025-11-12 | $11.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$6.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$7.59M 10-Q · filed 2025-08-11 | $2.87M derived: sum of 3 quarters · filed 2025-08-11 | -$213.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$742.00K 10-Q · filed 2025-05-15 | $9.71M derived: sum of 2 quarters · filed 2025-05-15 | $6.64M derived: sum of 3 quarters · filed 2025-05-15 | $10.93M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $7.38M derived: sum of 2 quarters · filed 2025-03-07 | $11.67M derived: sum of 3 quarters · filed 2025-03-07 | $11.06M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.22M derived: sum of 2 quarters · filed 2024-11-12 | $607.00K 10-Q · filed 2024-11-12 | -$2.92M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $3.69M 10-Q · filed 2024-08-12 | $157.00K derived: sum of 3 quarters · filed 2024-08-12 | $2.86M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$609.00K 10-Q · filed 2024-05-09 | -$4.14M derived: sum of 2 quarters · filed 2024-05-09 | -$1.43M derived: sum of 3 quarters · filed 2024-05-09 | $2.03M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$824.00K derived: sum of 2 quarters · filed 2024-03-28 | $2.64M derived: sum of 3 quarters · filed 2024-03-28 | $2.07M 10-K · filed 2024-03-28 |
| 2022-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $6.17M derived: sum of 2 quarters · filed 2023-11-01 | $5.59M 10-Q · filed 2023-11-01 | $5.35M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.89M 10-Q · filed 2023-08-08 | $2.65M derived: sum of 3 quarters · filed 2023-08-08 | $2.99M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$570.00K 10-Q · filed 2023-05-08 | -$811.00K derived: sum of 2 quarters · filed 2023-05-08 | -$474.00K derived: sum of 3 quarters · filed 2023-05-08 | -$462.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $96.00K derived: sum of 2 quarters · filed 2023-02-08 | $108.00K derived: sum of 3 quarters · filed 2023-02-08 | $1.62M 10-K · filed 2023-02-08 |
| 2021-09-30 | $337.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $349.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.86M 10-Q · filed 2022-11-08 | $2.13M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.52M 10-Q · filed 2022-08-08 | $1.79M derived: sum of 3 quarters · filed 2023-02-08 | $1.74M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | $1.51M 10-Q · filed 2022-05-05 | $1.78M derived: sum of 2 quarters · filed 2023-02-08 | $1.73M derived: sum of 3 quarters · filed 2023-02-08 | $1.49M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | $272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $219.00K derived: sum of 2 quarters · filed 2023-02-08 | -$18.00K derived: sum of 3 quarters · filed 2023-02-08 | -$187.00K 10-K · filed 2023-02-08 |
| 2020-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$290.00K derived: sum of 2 quarters · filed 2021-11-04 | -$459.00K 10-Q · filed 2021-11-04 | $983.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$237.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$406.00K 10-Q · filed 2021-08-09 | $1.04M derived: sum of 3 quarters · filed 2022-02-28 | $858.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$169.00K 10-Q · filed 2021-05-04 | $1.27M derived: sum of 2 quarters · filed 2022-02-28 | $1.09M derived: sum of 3 quarters · filed 2022-02-28 | $2.01M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.26M derived: sum of 2 quarters · filed 2022-02-28 | $2.18M derived: sum of 3 quarters · filed 2022-02-28 | -$394.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $736.00K derived: sum of 2 quarters · filed 2020-11-09 | -$1.84M 10-Q · filed 2020-11-09 | -$1.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $914.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$1.66M 10-Q · filed 2020-08-05 | -$1.23M derived: sum of 3 quarters · filed 2021-03-01 | -$1.71M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$2.57M 10-Q · filed 2020-05-06 | -$2.14M derived: sum of 2 quarters · filed 2021-03-01 | -$2.63M derived: sum of 3 quarters · filed 2021-03-01 | -$625.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$54.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.95M derived: sum of 3 quarters · filed 2021-03-01 | $2.49M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.52M derived: sum of 2 quarters · filed 2019-11-07 | $2.06M 10-Q · filed 2019-11-07 | $2.85M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.54M 10-Q · filed 2019-08-08 | $3.34M derived: sum of 3 quarters · filed 2020-02-27 | $4.28M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $544.00K 10-Q · filed 2019-05-09 | $1.34M derived: sum of 2 quarters · filed 2020-02-27 | $2.28M derived: sum of 3 quarters · filed 2020-02-27 | $2.26M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $792.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.74M derived: sum of 2 quarters · filed 2020-02-27 | $1.72M derived: sum of 3 quarters · filed 2020-02-27 | $1.90M 10-K · filed 2020-02-27 |
| 2017-09-30 | $944.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $925.00K derived: sum of 2 quarters · filed 2018-11-06 | $1.10M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $160.00K 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $179.00K 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $215.00K 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $293.00K 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |